Key facts
- This page summarizes Daniel B. Soland's Form 4 filing for ACADIA PHARMACEUTICALS INC (ACAD).
- 4 reported transactions and 3 derivative rows are listed below.
- Accepted by SEC: 02 Jun 2025, 18:05.
Daniel B. Soland - 29 May 2025 Form 4 Insider Report for ACADIA PHARMACEUTICALS INC (ACAD)
- Reporting relationship
- Director
- Issuer ticker
- ACAD
- Reported as of
- 29 May 2025
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 02 Jun 2025, 18:05:15 UTC
- Prior SEC filing
- 31 May 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Jennifer J. Rhodes, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Daniel B. Soland filed Form 4 for ACADIA PHARMACEUTICALS INC (ACAD) on 02 Jun 2025.
Change
- Previous filing in this sequence was filed on 31 May 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001318485
Primary reporting owner
SOLAND DANIEL B
- Relationship
- Director
- Address
- C/O ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO
- Signature
- /s/ Jennifer J. Rhodes, Attorney-in-Fact
- Signature date
- 02 Jun 2025
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ACAD
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +9,387
- Change %
- +27%
- Price
- Shares after
- 44,041
- Date
- 29 May 2025
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ACAD
transaction
Derivative
Restricted Stock Units
Options Exercise
- Transaction value
- $0
- Shares
- -9,387
- Change %
- -100%
- Price
- $0.000000
- Shares after
- 0
- Date
- 29 May 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 9,387
- Exercise price
- Footnotes
- F1, F2
ACAD
transaction
Derivative
Director Stock Options (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +13,793
- Change %
- Price
- $0.000000
- Shares after
- 13,793
- Date
- 29 May 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 13,793
- Exercise price
- $22.29
- Footnotes
- F3
ACAD
transaction
Derivative
Restricted Stock Units
Award
- Transaction value
- $0
- Shares
- +8,107
- Change %
- Price
- $0.000000
- Shares after
- 8,107
- Date
- 29 May 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 8,107
- Exercise price
- Footnotes
- F1, F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock.
Footnote F2
The restricted stock units vested in full on May 29, 2025, the date on which an annual meeting of stockholders was held.
Footnote F3
The shares subject to each stock option will vest quarterly over one year following the date of grant, with the final tranche vesting on the earlier of one year following the date of grant or the next annual meeting of stockholders.
Footnote F4
The restricted stock units will vest in full on the earlier of one year following the date of grant or the next annual meeting of stockholders.